%0 Journal Article
%T Management of donor-specific antibodies in lung transplantation.
%A Brandon W
%A Dunn C
%A Bollineni S
%A Joerns J
%A Lawrence A
%A Mohanka M
%A Timofte I
%A Torres F
%A Kaza V
%J Front Transplant
%V 2
%N 0
%D 2023
%M 38993917
暂无%R 10.3389/frtra.2023.1248284
%X The formation of antibodies against donor human leukocyte antigens poses a challenging problem both for donor selection as well as postoperative graft function in lung transplantation. These donor-specific antibodies limit the pool of potential donor organs and are associated with episodes of antibody-mediated rejection, chronic lung allograft dysfunction, and increased mortality. Optimal management strategies for clearance of DSAs are poorly defined and vary greatly by institution; most of the data supporting any particular strategy is limited to small-scale retrospective cohort studies. A typical approach to antibody depletion may involve the use of high-dose steroids, plasma exchange, intravenous immunoglobulin, and possibly other immunomodulators or small-molecule therapies. This review seeks to define the current understanding of the significance of DSAs in lung transplantation and outline the literature supporting strategies for their management.